WO2004008099A3 - METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES - Google Patents

METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES Download PDF

Info

Publication number
WO2004008099A3
WO2004008099A3 PCT/US2003/021590 US0321590W WO2004008099A3 WO 2004008099 A3 WO2004008099 A3 WO 2004008099A3 US 0321590 W US0321590 W US 0321590W WO 2004008099 A3 WO2004008099 A3 WO 2004008099A3
Authority
WO
WIPO (PCT)
Prior art keywords
her2
responsive
treatment
methods
erbb2 antibodies
Prior art date
Application number
PCT/US2003/021590
Other languages
French (fr)
Other versions
WO2004008099A8 (en
WO2004008099A2 (en
Inventor
Hans Koll
Birgit Bossenmaier
Hans-Joachim Mueller
Mark X Sliwkowski
Stephen Michael Kelsey
Original Assignee
Genentech Inc
Hoffmann La Roche
Hans Koll
Birgit Bossenmaier
Hans-Joachim Mueller
Mark X Sliwkowski
Stephen Michael Kelsey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=30118578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2004008099(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to CA2490758A priority Critical patent/CA2490758C/en
Priority to EP03755724A priority patent/EP1585966B8/en
Priority to JP2004521625A priority patent/JP5069843B2/en
Priority to BRPI0312534-3A priority patent/BR0312534A/en
Priority to ES03755724T priority patent/ES2376165T3/en
Priority to DK03755724.6T priority patent/DK1585966T3/en
Priority to NZ537660A priority patent/NZ537660A/en
Priority to AU2003273218A priority patent/AU2003273218C1/en
Priority to MXPA05000403A priority patent/MXPA05000403A/en
Application filed by Genentech Inc, Hoffmann La Roche, Hans Koll, Birgit Bossenmaier, Hans-Joachim Mueller, Mark X Sliwkowski, Stephen Michael Kelsey filed Critical Genentech Inc
Priority to SI200332099T priority patent/SI1585966T1/en
Priority to AT03755724T priority patent/ATE535254T1/en
Priority to HU0600340A priority patent/HUP0600340A3/en
Publication of WO2004008099A2 publication Critical patent/WO2004008099A2/en
Priority to IL165952A priority patent/IL165952A/en
Priority to NO20050775A priority patent/NO337855B1/en
Publication of WO2004008099A8 publication Critical patent/WO2004008099A8/en
Publication of WO2004008099A3 publication Critical patent/WO2004008099A3/en
Priority to HK06104646.4A priority patent/HK1082687A1/en
Priority to IL219381A priority patent/IL219381A/en
Priority to NO20151725A priority patent/NO340576B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Tumors are identified as responsive to treatment with anti-HER2 antibodies by detecting the presence of a HER2/HER3 and/or HER2/HER1 protein complex or for HER2 phosphorylation in a sample of tumor cells. Patients suffering from a tumor comprising HER/2/HER1 and/or HER2/HER3 heterodimers and/or HER2 phosphorylation are treated with anti-HER2 antibodies, such as rhuMAb 2C4.
PCT/US2003/021590 2002-07-11 2003-07-11 METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES WO2004008099A2 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
BRPI0312534-3A BR0312534A (en) 2002-07-15 2003-07-11 Tumor identification method, Tumor cell identification method, Method for predicting the response of an individual diagnosed with a her2-positive tumor, Method for identification of an individual responsive to anti-her2 antibody treatment and Methods of treatment of a patient and article of manufacture
AT03755724T ATE535254T1 (en) 2002-07-15 2003-07-11 TREATING CANCER WITH THE ANTI-ERBB2 ANTIBODY RHUMAB 2C4
SI200332099T SI1585966T1 (en) 2002-07-15 2003-07-11 Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4
HU0600340A HUP0600340A3 (en) 2002-07-15 2003-07-11 Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
EP03755724A EP1585966B8 (en) 2002-07-15 2003-07-11 Treatment of cancer with the anti-ErbB2 antibody rhuMAb 2C4
DK03755724.6T DK1585966T3 (en) 2002-07-15 2003-07-11 Treatment of cancer with the anti-ErbB2 antibody rhuMab 2C4
NZ537660A NZ537660A (en) 2002-07-15 2003-07-11 Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
AU2003273218A AU2003273218C1 (en) 2002-07-15 2003-07-11 Methods for identifying tumors that are responsive to treatment with anti-ErbB2 antibodies
MXPA05000403A MXPA05000403A (en) 2002-07-15 2003-07-11 METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES.
CA2490758A CA2490758C (en) 2002-07-15 2003-07-11 Dosage form of recombinant humanized monoclonal antibody 2c4
JP2004521625A JP5069843B2 (en) 2002-07-15 2003-07-11 Method for identifying tumors responsive to treatment with anti-ErbB2 antibodies
ES03755724T ES2376165T3 (en) 2002-07-15 2003-07-11 TREATMENT OF THE C�? NCER WITH THE ANTIBODY DIRECTED AGAINST ERBB2 RHUMAB 2C4.
IL165952A IL165952A (en) 2002-07-15 2004-12-23 Recombinant humanized antibody 2c4 and uses thereof
NO20050775A NO337855B1 (en) 2002-07-15 2005-02-14 Recombinant humanized antibody 2C4 (rhuMab 2C4) for use in a method of treating cancer in a patient and use thereof for the manufacture of a drug
HK06104646.4A HK1082687A1 (en) 2002-07-15 2006-04-19 Treatment of cancer with the anti-erbb2 antibody rhumab 2c4
IL219381A IL219381A (en) 2002-07-15 2012-04-24 Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies
NO20151725A NO340576B1 (en) 2002-07-11 2015-12-15 Recombinant humanized antibody 2C4 (rhuMab 2C4) for use with a second, various growth inhibitory anti-ErbB2 antibody in a method of treating cancer in a patient and use thereof for the manufacture of a drug

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39629002P 2002-07-15 2002-07-15
US60/396,290 2002-07-15
US48004303P 2003-06-20 2003-06-20
US60/480,043 2003-06-20

Publications (3)

Publication Number Publication Date
WO2004008099A2 WO2004008099A2 (en) 2004-01-22
WO2004008099A8 WO2004008099A8 (en) 2005-02-17
WO2004008099A3 true WO2004008099A3 (en) 2005-09-01

Family

ID=30118578

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/021590 WO2004008099A2 (en) 2002-07-11 2003-07-11 METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES

Country Status (21)

Country Link
US (2) US20040106161A1 (en)
EP (2) EP1585966B8 (en)
JP (3) JP5069843B2 (en)
CN (2) CN102295703A (en)
AT (1) ATE535254T1 (en)
AU (2) AU2003273218C1 (en)
BR (1) BR0312534A (en)
CA (1) CA2490758C (en)
CY (2) CY1112631T1 (en)
DK (2) DK1585966T3 (en)
ES (2) ES2376165T3 (en)
HK (1) HK1082687A1 (en)
HU (1) HUP0600340A3 (en)
IL (2) IL165952A (en)
MX (1) MXPA05000403A (en)
NO (1) NO337855B1 (en)
NZ (1) NZ537660A (en)
PL (1) PL214010B1 (en)
PT (2) PT1585966E (en)
RU (2) RU2338751C2 (en)
WO (1) WO2004008099A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085622B2 (en) 2010-09-03 2015-07-21 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
US7393823B1 (en) 1999-01-20 2008-07-01 Oregon Health And Science University HER-2 binding antagonists
US7625859B1 (en) * 2000-02-16 2009-12-01 Oregon Health & Science University HER-2 binding antagonists
CN102698265A (en) 2000-05-19 2012-10-03 杰南技术公司 Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US20040229294A1 (en) 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
US20090111127A1 (en) * 2002-05-21 2009-04-30 Monogram Biosciences Inc. Surface Receptor Complexes as Biomarkers
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
WO2004092353A2 (en) * 2003-04-01 2004-10-28 Monogram Biosciences, Inc. Surface receptor complexes as biomarkers
US7402398B2 (en) * 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
US20100291594A1 (en) * 2003-07-17 2010-11-18 Laboratory Corporation Of America Holdings ErbB Surface Receptor Complexes as Biomarkers
NZ545873A (en) * 2003-08-11 2009-05-31 Monogram Biosciences Inc Detecting and profiling molecular complexes
US7402399B2 (en) 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
US7329495B2 (en) 2004-06-09 2008-02-12 Board Of Regents, The University Of Texas System Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors
SV2006002143A (en) * 2004-06-16 2006-01-26 Genentech Inc USE OF AN ANTIBODY FOR THE TREATMENT OF CANCER RESISTANT TO PLATINUM
KR20160096228A (en) 2004-07-22 2016-08-12 제넨테크, 인크. Her2 antibody composition
US20080206231A1 (en) * 2004-10-05 2008-08-28 Oregon Health And Science University Compositions and Methods for Treating Disease
DE602005026143D1 (en) * 2004-10-06 2011-03-10 Wellstat Biologics Corp RECOGNITION OF AN INCREASED MIRROR OF HER-2 / NEU PROTEINS IN CIRCULATING CANCER CELLS AND THEIR TREATMENT
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
WO2006045991A1 (en) * 2004-10-25 2006-05-04 Astrazeneca Ab Method to predict whether a tumor will react to a chemotherapeutic treatment
ZA200704796B (en) * 2004-12-07 2008-11-26 Genentech Inc Selecting patients for therapy with a HER inhibitor
EP3698807A1 (en) * 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies
AU2006216732C1 (en) * 2005-02-23 2017-07-20 Genentech, Inc. Extending time to disease progression or survival in cancer patients using a HER dimerization inhibitor
WO2006096861A2 (en) * 2005-03-08 2006-09-14 Genentech, Inc. METHODS FOR IDENTIFYING TUMORS RESPONSIVE TO TREATMENT WITH HER DIMERIZATION INHIBITORS (HDIs)
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc Herceptin(r) adjuvant treatment
US20070009976A1 (en) * 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
PE20070207A1 (en) 2005-07-22 2007-03-09 Genentech Inc COMBINED TREATMENT OF TUMORS THAT EXPRESS HER
US7700299B2 (en) * 2005-08-12 2010-04-20 Hoffmann-La Roche Inc. Method for predicting the response to a treatment
CA2647843A1 (en) 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of proteins from circulating neoplastic cells
WO2007121464A2 (en) * 2006-04-18 2007-10-25 Wellstat Biologics Corporation Detection of circulating endothelial cells
WO2008001802A1 (en) * 2006-06-27 2008-01-03 Asahi Kasei Kabushiki Kaisha Substrate for biological fluid treatment
WO2011008990A1 (en) 2009-07-15 2011-01-20 Prometheus Laboratories Inc. Drug selection for gastric cancer therapy using antibody-based arrays
BRPI0717416A2 (en) 2006-09-21 2013-11-12 Prometheus Lab Inc METHOD FOR PERFORMING A HIGH PRODUCTIVITY COMPLEX IMMUNOASON, AND
EP2132229B1 (en) 2007-03-01 2016-05-11 Symphogen A/S Recombinant anti-epidermal growth factor receptor antibody compositions
WO2008109440A2 (en) 2007-03-02 2008-09-12 Genentech, Inc. Predicting response to a her dimerisation inhibitor based on low her3 expression
US20090304590A1 (en) * 2007-05-29 2009-12-10 Wyeth Therapeutic compositions and methods
US20090258005A1 (en) * 2007-05-29 2009-10-15 Trubion Pharmaceuticals Inc. Therapeutic compositions and methods
WO2008154249A2 (en) * 2007-06-08 2008-12-18 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
RU2519647C2 (en) * 2007-07-13 2014-06-20 Нестек С.А. Selection of medications for lung cancer therapy by means of antibody-based matrices
JP5559695B2 (en) * 2007-11-09 2014-07-23 ノバルティス アーゲー Use of anti-CD40 antibodies
EP2650311A3 (en) 2007-11-27 2014-06-04 Ablynx N.V. Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same
US10416162B2 (en) 2007-12-20 2019-09-17 Monogram Biosciences, Inc. Her2 diagnostic methods
CA2710680C (en) * 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
US20140127200A1 (en) * 2008-01-03 2014-05-08 The Scripps Research Institute Multispecific Antibody Targeting and Multivalency Through Modular Recognition Domains
TWI472339B (en) 2008-01-30 2015-02-11 Genentech Inc Composition comprising antibody that binds to domain ii of her2 and acidic variants thereof
CA2923248A1 (en) 2008-02-25 2009-09-03 Nestec S.A. Methods for detecting truncated receptors
JP5800454B2 (en) * 2008-05-23 2015-10-28 株式会社ノエビア External preparation for skin, oral preparation, antioxidant, anti-aging agent, and immunostimulant
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
CA2729796C (en) 2008-07-08 2017-07-04 George Mason Intellectual Properties, Inc. Phosphorylated c-erbb2 as a superior predictive theranostic marker for the diagnosis and treatment of cancer
MX2011001290A (en) * 2008-08-05 2011-06-21 A L M Holding Company Process for cold-in-place recycling using foamed asphalt and lubrication additive.
CN102137874B (en) 2008-08-29 2015-02-18 西福根有限公司 Recombinant anti-epidermal growth factor receptor antibody compositions
WO2010065568A2 (en) 2008-12-01 2010-06-10 Laboratory Corporation Of America Holdings METHODS AND ASSAYS FOR MEASURING p95 AND/OR p95 IN A SAMPLE AND ANTIBODIES SPECIFIC FOR p95
US20100233732A1 (en) * 2009-01-15 2010-09-16 Laboratory Corporation Of America Holdings Methods of Determining Patient Response By Measurement of HER-2 Expression
ES2535723T3 (en) * 2009-01-15 2015-05-14 Laboratory Corporation Of America Holdings Methods for determining the patient's response by measuring Her-3
ES2572728T3 (en) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Bispecific anti-HER antibodies
CA2761777A1 (en) * 2009-05-14 2010-11-18 Prometheus Laboratories Inc. Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy
JP5705836B2 (en) 2009-05-29 2015-04-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Modulators for HER2 signaling in gastric cancer patients expressing HER2
JP5981853B2 (en) 2010-02-18 2016-08-31 ジェネンテック， インコーポレイテッド Neuregulin antagonists and their use in the treatment of cancer
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
US9155802B2 (en) * 2010-11-01 2015-10-13 Symphogen A/S Pan-HER antibody composition
EP2643353A1 (en) 2010-11-24 2013-10-02 Novartis AG Multispecific molecules
SG191153A1 (en) 2010-12-23 2013-07-31 Hoffmann La Roche Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
US9719995B2 (en) 2011-02-03 2017-08-01 Pierian Holdings, Inc. Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
MX2014001766A (en) 2011-08-17 2014-05-01 Genentech Inc Neuregulin antibodies and uses thereof.
WO2013033623A1 (en) 2011-09-02 2013-03-07 Nestec S.A. Profiling of signal pathway proteins to determine therapeutic efficacy
JP6271432B2 (en) 2011-09-30 2018-01-31 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Anti-ErbB3 antibody and use thereof
US9273143B2 (en) 2011-09-30 2016-03-01 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EGFR antibody
US9828635B2 (en) 2011-10-06 2017-11-28 Aveo Pharmaceuticals, Inc. Predicting tumor response to anti-ERBB3 antibodies
DK2766040T3 (en) 2011-10-14 2019-07-22 Hoffmann La Roche Pertuzumab, trastuzumab, docetaxel and carboplatin for the treatment of early breast cancer
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
US9220775B2 (en) * 2011-11-23 2015-12-29 Medimmune Llc Binding molecules specific for HER3 and uses thereof
CA2857114A1 (en) 2011-11-30 2013-06-06 Genentech, Inc. Erbb3 mutations in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
JP2015514710A (en) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Diagnosis and treatment of HER3 inhibitors
BR112014027291A2 (en) 2012-05-02 2017-08-08 Symphogen As humanized pan-her antibody compositions
TW201843172A (en) * 2012-06-25 2018-12-16 美商再生元醫藥公司 Anti-egfr antibodies and uses thereof
JP2015532306A (en) 2012-10-15 2015-11-09 チューリッヒ大学 Bispecific HER2 ligand for cancer therapy
EP2719706A1 (en) 2012-10-15 2014-04-16 Universität Zürich Bispecific HER2 ligands for cancer therapy
MX363188B (en) 2012-11-30 2019-03-13 Hoffmann La Roche Identification of patients in need of pd-l1 inhibitor cotherapy.
EA201890895A1 (en) 2013-03-15 2019-02-28 Зинджения, Инк. MULTIVALENT AND MONOVALENT MULTIS-SPECIFIC COMPLEXES AND THEIR APPLICATION
CA2908515A1 (en) * 2013-04-05 2014-10-09 Laboratory Corporation Of America Holdings Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation
AR095863A1 (en) * 2013-04-16 2015-11-18 Genentech Inc VARIATIONS OF PERTUZUMAB, ITS ASSESSMENT, METHOD OF TREATMENT, METHOD OF PREPARATION AND ARTICLE OF MANUFACTURE
WO2015048008A2 (en) 2013-09-24 2015-04-02 Medimmune, Llc Binding molecules specific for her3 and uses thereof
WO2015100459A2 (en) 2013-12-27 2015-07-02 Merrimack Pharmaceuticals, Inc. Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies
WO2015157634A1 (en) 2014-04-11 2015-10-15 Kolltan Pharmaceuticals, Inc. Anti-erbb antibodies and methods of use thereof
EP3134440A1 (en) 2014-04-25 2017-03-01 F. Hoffmann-La Roche AG Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab
CN105985435B (en) 2015-01-30 2019-10-15 嘉和生物药业有限公司 The mutant antibodies and its encoding gene of full source of people HER2 antibody and application
EP3302551A2 (en) 2015-05-30 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating her2-positive locally advanced or previously untreated metastatic breast cancer
US10184006B2 (en) 2015-06-04 2019-01-22 Merrimack Pharmaceuticals, Inc. Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors
WO2017087280A1 (en) 2015-11-16 2017-05-26 Genentech, Inc. Methods of treating her2-positive cancer
JPWO2017141987A1 (en) * 2016-02-19 2018-12-06 コニカミノルタ株式会社 A nonclinical test method characterized by quantitative evaluation of laboratory animal specimens
EP3454863A1 (en) 2016-05-10 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
US10377833B2 (en) 2016-07-22 2019-08-13 Beijing Mabworks Biotech Co., Ltd. Bispecific anti-HER2 antibody
CN107446045A (en) 2016-07-22 2017-12-08 北京天广实生物技术股份有限公司 A kind of anti-HER2 antibody, its pharmaceutical composition and purposes
JP2019532999A (en) 2016-11-04 2019-11-14 ジェネンテック， インコーポレイテッド Treatment of HER2-positive breast cancer
CN110099926A (en) 2016-12-28 2019-08-06 豪夫迈·罗氏有限公司 The treatment of advanced stage HER2 expressivity cancer
RU2750821C2 (en) 2017-01-17 2021-07-05 Дженентек, Инк. Anti-her2 antibody drugs for subcutaneous injection
FI3589661T3 (en) 2017-03-02 2024-01-31 Genentech Inc Adjuvant treatment of her2-positive breast cancer
CN110536969A (en) 2017-04-24 2019-12-03 豪夫迈·罗氏有限公司 ERBB2/HER2 mutation in cross-film or nearly film domain
EP3807640A4 (en) * 2018-06-14 2022-04-13 Memorial Sloan Kettering Cancer Center Methods for predicting responsiveness of lung cancer patients to her2-targeting therapies
WO2020023486A1 (en) 2018-07-23 2020-01-30 Trevi Therapeutics, Inc. Treatment of chronic cough, breathlessness and dyspnea
BR112021003472A2 (en) 2018-09-06 2021-05-18 Daiichi Sankyo Company, Limited cyclic dinucleotide derivative and antibody-drug conjugate thereof
EP3864054A1 (en) 2018-10-08 2021-08-18 Universität Zürich Her2-binding tetrameric polypeptides
WO2021188578A1 (en) * 2020-03-16 2021-09-23 University Of Southern California Screening methods to identify small molecule compounds that promote or inhibit the growth of circulating tumor cells, and uses thereof
TW202241454A (en) 2021-02-01 2022-11-01 日商第一三共股份有限公司 Novel method for producing antibody-immunostimulator conjugate
BR112023017365A2 (en) 2021-03-12 2023-10-03 Daiichi Sankyo Co Ltd GLYCAN AND METHOD FOR PRODUCING MEDICINE CONTAINING GLYCAN

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US197835A (en) * 1877-12-04 Improvement in dovetailing and grooving machines
US229380A (en) * 1880-06-29 John charles
US190689A (en) * 1877-05-15 Improvement in car-brakes
US126818A (en) * 1872-05-14 Improvement in carpet-stretchers
US229294A (en) * 1880-06-29 woolnoug-h
US229293A (en) * 1880-06-29 Swinging can
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
CU22545A1 (en) 1994-11-18 1999-03-31 Centro Inmunologia Molecular OBTAINING A CHEMICAL AND HUMANIZED ANTIBODY AGAINST THE RECEPTOR OF THE EPIDERMAL GROWTH FACTOR FOR DIAGNOSTIC AND THERAPEUTIC USE
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4474683A (en) 1981-08-10 1984-10-02 Armour-Dial, Inc. Soap making process
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
AU3934085A (en) 1984-01-30 1985-08-09 Icrf Patents Ltd. Improvements relating to growth factors
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4968603A (en) 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8705477D0 (en) 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4975278A (en) 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5283187A (en) 1987-11-17 1994-02-01 Brown University Research Foundation Cell culture-containing tubular capsule produced by co-extrusion
US4892538A (en) 1987-11-17 1990-01-09 Brown University Research Foundation In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
DE68925971T2 (en) 1988-09-23 1996-09-05 Cetus Oncology Corp CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646437B1 (en) 1989-04-28 1991-08-30 Transgene Sa NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
DE69029036T2 (en) 1989-06-29 1997-05-22 Medarex Inc SPECIFIC REAGENTS FOR AIDS THERAPY
CA2066428C (en) 1989-09-08 2000-11-28 Bert Vogelstein Structural alterations of the egf receptor gene in human gliomas
DE68926248T2 (en) 1989-09-29 1996-12-19 Oncogene Science Inc p100 "new" human protein and the use of this protein for the detection of preneoplasmic or neoplasmic in humans
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
IL101943A0 (en) 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
ES2206447T3 (en) 1991-06-14 2004-05-16 Genentech, Inc. HUMANIZED ANTIBODY FOR HEREGULINE.
US5264586A (en) 1991-07-17 1993-11-23 The Scripps Research Institute Analogs of calicheamicin gamma1I, method of making and using the same
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
JPH07501451A (en) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド Multivalent antigen binding protein
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
ATE244763T1 (en) 1992-02-11 2003-07-15 Cell Genesys Inc ACHIEVEMENT OF HOMOZYGOTE THROUGH TARGETED GENETIC EVENTS
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
AU4025193A (en) 1992-04-08 1993-11-18 Cetus Oncology Corporation Humanized C-erbB-2 specific antibodies
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
IL105914A0 (en) 1992-06-04 1993-10-20 Univ California Methods and compositions for in vivo gene therapy
AU687346B2 (en) 1992-06-30 1998-02-26 Oncologix, Inc. A combination of anti-erbB-2 monoclonal antibodies and method of using
ATE149570T1 (en) 1992-08-17 1997-03-15 Genentech Inc BISPECIFIC IMMUNOADHESINS
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
CA2103323A1 (en) 1992-11-24 1994-05-25 Gregory D. Plowman Her4 human receptor tyrosine kinase
ATE186219T1 (en) 1993-03-24 1999-11-15 Berlex Biosciences COMBINATION OF ANTIHORMONAL AND BINDING MOLECULES FOR CANCER TREATMENT
AU6527894A (en) 1993-03-30 1994-10-24 Trustees Of The University Of Pennsylvania, The Prevention of tumors with monoclonal antibodies against (neu)
US6287784B1 (en) 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
AU697142B2 (en) 1993-11-23 1998-10-01 Genentech Inc. Protein tyrosine kinases named Rse
ATE163231T1 (en) 1993-11-23 1998-02-15 Genentech Inc KINASE RECEPTOR ACTIVATION TEST
ATE207366T1 (en) 1993-12-24 2001-11-15 Merck Patent Gmbh IMMUNOCONJUGATES
PT699237E (en) 1994-03-17 2003-07-31 Merck Patent Gmbh ANTI-EGFR CHAIN FVS AND ANTI-EGFR ANTIBODIES
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
BR9508409A (en) 1994-07-21 1997-12-23 Akzo Nobel Nv Storage stable transportable peroxide composition and use of an organic peroxide formulation
US5910486A (en) 1994-09-06 1999-06-08 Uab Research Foundation Methods for modulating protein function in cells using, intracellular antibody homologues
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
US6214388B1 (en) 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
AU4289496A (en) 1994-12-02 1996-06-19 Chiron Corporation Method of promoting an immune response with a bispecific antibody
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP2295415A1 (en) 1995-03-30 2011-03-16 OSI Pharmaceuticals, Inc. Quinazoline derivatives
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5837234A (en) 1995-06-07 1998-11-17 Cytotherapeutics, Inc. Bioartificial organ containing cells encapsulated in a permselective polyether suflfone membrane
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US5977322A (en) 1995-06-14 1999-11-02 The Regents Of The University Of California High affinity human antibodies to tumor antigens
JPH11510170A (en) 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド Protein Formula
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
PT896586E (en) 1996-03-27 2007-01-31 Genentech Inc Erbb3 antibodies
US5968511A (en) * 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
PL190489B1 (en) 1996-04-12 2005-12-30 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
US5922845A (en) 1996-07-11 1999-07-13 Medarex, Inc. Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
UA73073C2 (en) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Substituted 3-cyan chinolines
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AU9805398A (en) 1997-10-15 1999-05-03 Children's Medical Center Corporation Novel human egf receptors and use thereof
JP2002503814A (en) * 1998-02-12 2002-02-05 イムニベスト・コーポレイション Methods and reagents for rapid and efficient isolation of circulating cancer cells
US6514700B1 (en) 1999-04-30 2003-02-04 Aclara Biosciences, Inc. Nucleic acid detection using degradation of a tagged sequence
US6322980B1 (en) 1999-04-30 2001-11-27 Aclara Biosciences, Inc. Single nucleotide detection using degradation of a fluorescent sequence
US6627400B1 (en) * 1999-04-30 2003-09-30 Aclara Biosciences, Inc. Multiplexed measurement of membrane protein populations
AU5003200A (en) 1999-05-14 2000-12-05 United States Of America As Represented By The Department Of Veterans Affairs, The Isolation and characterization of epidermal growth factor related protein
US7049410B2 (en) 1999-05-14 2006-05-23 Majumdar Adhip P N Antibodies to a novel EGF-receptor related protein (ERRP)
DK2283866T3 (en) * 1999-06-25 2015-05-18 Genentech Inc METHODS OF TREATMENT USING ANTI-ERBB ANTIBODY-MAYTANSINOID CONJUGATES
US7041292B1 (en) * 1999-06-25 2006-05-09 Genentech, Inc. Treating prostate cancer with anti-ErbB2 antibodies
US6949245B1 (en) * 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1189641B1 (en) 1999-06-25 2009-07-29 Genentech, Inc. HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES
ATE373017T1 (en) * 1999-07-30 2007-09-15 Medarex Inc THERAPEUTIC COMPOUNDS CONSISTING OF FC RECEPTOR-BINDING ACTIVE INGREDIENTS
ES2330301T3 (en) * 1999-08-27 2009-12-09 Genentech, Inc. DOSAGES FOR TREATMENT WITH ANTI-ERBB2 ANTIBODIES.
CN102698265A (en) 2000-05-19 2012-10-03 杰南技术公司 Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
US20020119148A1 (en) 2000-09-01 2002-08-29 Gerritsen Mary E. ErbB4 antagonists
WO2002087619A1 (en) * 2001-04-27 2002-11-07 Takeda Chemical Industries, Ltd. Preventive/therapeutic method for cancer
JP2004002211A (en) * 2001-04-27 2004-01-08 Takeda Chem Ind Ltd Method for prophylaxis and treatment of cancer
US20030190689A1 (en) * 2002-04-05 2003-10-09 Cell Signaling Technology,Inc. Molecular profiling of disease and therapeutic response using phospho-specific antibodies
US20040229380A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB heterodimers as biomarkers
US20040229293A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
US20040229294A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui ErbB surface receptor complexes as biomarkers
AU2003251597A1 (en) * 2002-06-19 2004-01-06 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
ES2332310T3 (en) * 2002-07-25 2010-02-02 Aclara Biosciences, Inc. RECEIVER OLIGOMERIZATION DETECTION.
EP3698807A1 (en) * 2005-01-21 2020-08-26 Genentech, Inc. Fixed dosing of her antibodies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5811098A (en) * 1992-11-24 1998-09-22 Bristol-Myers Squibb Company Antibodies to HER4, human receptor tyrosine kinase
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
AGUS D.B. ET AL: "Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth", CANCER CELL, vol. 2, August 2002 (2002-08-01), pages 127 - 137, XP002988666 *
QIAN X. ET AL: "p185c-neu and Epidermal Growth Factor Receptor Associated into Structure Composed of Activated Kinases", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 89, February 1992 (1992-02-01), pages 1330 - 1334, XP002988667 *
SLIKOWSKI M.X. ET AL: "Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 20, 20 May 1994 (1994-05-20), pages 14661 - 14665, XP000605388 *
TZAHAR E. ET AL: "The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands", BIOCHEMICA ET BIOPHYSICA ACTA, vol. 1377, 20 February 1998 (1998-02-20), pages M29 - M34, XP004281795 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9085622B2 (en) 2010-09-03 2015-07-21 Glaxosmithkline Intellectual Property Development Limited Antigen binding proteins

Also Published As

Publication number Publication date
AU2003273218A1 (en) 2004-02-02
JP5069843B2 (en) 2012-11-07
CY1113260T1 (en) 2016-04-13
ES2376165T3 (en) 2012-03-09
PT1585966E (en) 2012-02-20
ES2392525T3 (en) 2012-12-11
EP1585966B8 (en) 2012-03-07
NO337855B1 (en) 2016-07-04
PL377743A1 (en) 2006-02-20
EP1585966A2 (en) 2005-10-19
DK1585966T3 (en) 2012-02-20
HUP0600340A2 (en) 2006-08-28
NO20050775L (en) 2005-02-14
ATE535254T1 (en) 2011-12-15
EP1585966B1 (en) 2011-11-30
CA2490758A1 (en) 2004-01-22
HUP0600340A3 (en) 2011-06-28
WO2004008099A8 (en) 2005-02-17
RU2005103824A (en) 2005-08-27
JP5678005B2 (en) 2015-02-25
JP2014237667A (en) 2014-12-18
MXPA05000403A (en) 2005-07-22
JP2006508336A (en) 2006-03-09
PT2263691E (en) 2012-11-12
IL165952A0 (en) 2006-01-15
AU2003273218B2 (en) 2009-11-26
JP2012232987A (en) 2012-11-29
PL214010B1 (en) 2013-06-28
RU2338751C2 (en) 2008-11-20
CN101711866A (en) 2010-05-26
IL219381A0 (en) 2012-06-28
RU2008128244A (en) 2010-01-20
NZ537660A (en) 2008-12-24
IL219381A (en) 2014-11-30
AU2010200692A1 (en) 2010-03-18
EP1585966A4 (en) 2007-02-21
CY1112631T1 (en) 2016-02-10
EP2263691A1 (en) 2010-12-22
BR0312534A (en) 2007-03-13
AU2003273218C1 (en) 2019-01-17
HK1082687A1 (en) 2006-06-16
CA2490758C (en) 2014-09-23
EP2263691B1 (en) 2012-08-29
US20040106161A1 (en) 2004-06-03
US20110117096A1 (en) 2011-05-19
IL165952A (en) 2012-06-28
CN102295703A (en) 2011-12-28
DK2263691T3 (en) 2012-10-22
WO2004008099A2 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
WO2004008099A8 (en) METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
IL254264A (en) Dosages for treatment with anti-erbb2 antibodies
EP1585966A3 (en) METHODS FOR IDENTIFYING TUMORS THAT ARE RESPONSIVE TO TREATMENT WITH ANTI-ErbB2 ANTIBODIES
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
HK1074634A1 (en) Internalizing antibodies specific for the raag10 cell surface target
WO2005080431A3 (en) Monoclonal antibodies that specifically bind to folate receptor alpha
MA30654B1 (en) TUMOR THERAPY WITH ANTI-VEGF ANTIBODIES
AU7074698A (en) Detection and modulation of the iaps and naip for the diagnosis and treatment ofproliferative disease
NZ508456A (en) FAP alpha-specific antibody with frame-work modifications resulting in improved producibility
ATE483978T1 (en) ANTI-EPHA2 ANTIBODIES AS A CANCER DIAGNOSTIC
WO2000035950A3 (en) Reagents and methods useful for detecting diseases of the breast
HK1126278A1 (en) Identification of non-small cell lung carcinoma (nsclc) tumors expressing pdgfr-alpha pdgfr(nsclc)
WO2002074251A3 (en) Monoclonal antibody therapy for pancreas cancer
WO2002077609A3 (en) Identification of compounds for the treatment or prevention of proliferative diseases
WO2004003155A3 (en) Humanized anti-tag-72 cc49 for diagnosis and therapy of human tumors
DE69823660D1 (en) METHOD FOR IDENTIFYING TUMORANTIGENS WITH AUTOANTIBODIES IN SERUM
WO2004069860A3 (en) Isg15-conjugated proteins
WO2003024302A3 (en) Detection and treatment of cancers of breast
WO2004083387A3 (en) Anti-ganglioside antibodies and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 4064/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2490758

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003273218

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2005/00126

Country of ref document: ZA

Ref document number: 200500126

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/000403

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 377743

Country of ref document: PL

WWE Wipo information: entry into national phase

Ref document number: 1-2005-500093

Country of ref document: PH

Ref document number: 537660

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004521625

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003755724

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2005103824

Country of ref document: RU

Kind code of ref document: A

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 04/2004 UNDER (71) REPLACE "GENETECH" BY "GENENTECH"

WWE Wipo information: entry into national phase

Ref document number: 20038216256

Country of ref document: CN

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003755724

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0312534

Country of ref document: BR